-
Final Phase II results of Valneva’s Clostridium difficile vaccine candidate confirm positive initial Phase II data that were released at the end of 2015
-
The Phase II study design, which enrolled 500 subjects, had been agreed with regulators with the aim of supporting a progression into Phase III
-
Valneva reaffirms its expectation to enter into a partnering agreement for C. difficile program by the end of year
LYON, France I July 25, 2016 I Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, today announced the successful completion of its Phase II study for its prophylactic vaccine candidate VLA84 targeting primary prevention of C. difficile infection (CDI), which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
Valneva previously announced positive top-line data from the Phase II study at the end of 2015. These initial results, which included data up to Day 56 following initial vaccination, were presented at the American Society of Microbiology’s annual meeting, ASM Microbe 2016, on June 17 in Boston. VLA84 was immunogenic at all doses and formulations tested, in that Immunoglobulin G (IgG) and functional (neutralizing) antibody responses were observed. The study met its primary endpoint in terms of identifying the dose/formulation with the highest seroconversion1 rate against both toxins A and B and confirmed the favorable safety profile observed in Phase I.
Final Phase II results included the follow-up of study participants until Day 210. This long-term data confirmed the optimal vaccine dose and formulation that had been previously identified (high-dose formulation without adjuvant) with an immunogenicity profile at Day 210 in line with expectations. Long-term safety concerns were not seen in any of the different vaccine doses tested.
Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva, commented, “We are pleased with the positive final data generated in this Phase II trial and believe that our C. difficile candidate has the potential to address a growing unmet medical need. Infections caused by C. difficile are responsible for almost 30 thousand deaths every year in the US alone2. There is currently no vaccine on the market that can protect patients and we are determined to find a partner to advance our vaccine candidate further.”
Valneva’s C. difficile Phase II trial was a randomized, placebo-controlled, observer-blind multi-center trial designed to further study and confirm the candidate vaccine’s safety, immunogenicity and proposed doses of immunizations in two different age groups (50 to 64 years of age and 65 years of age and older). The trial was conducted in Germany and the United States under an Investigational New Drug application (IND) and enrolled 500 volunteers who were randomized in several study groups: low-dose vaccine without adjuvant, high-dose vaccine with or without adjuvant (Aluminium hydroxide), or placebo.
Valneva confirmed Phase III readiness through an independent Scientific Advisory Board (SAB) and is ready to support an end-of Phase II meeting (EOP2 meeting) with the regulatory authorities once the final Phase III design has been agreed with a partner. As announced previously, Valneva expects to enter into a partnering agreement for this program by year end 2016.
Currently, no vaccine against C. difficile is approved and antibiotic treatment of the established disease has significant limitations with recurrence in approximately 20% of cases3. The incidence of nosocomial infections is steadily increasing due to the growing number of medical interventions. Valneva estimates that the total market potential for prophylactic C. difficile products may exceed $1 billion annually.
About Clostridium Difficile
C. difficile is a potentially life-threatening bacterium that causes diarrhea and can lead to serious intestinal diseases. It is estimated that 450,000 cases occur annually in the US, and close to 30.000 patients die within 30 days of the diagnosis4.
Beyond the substantial morbidity and mortality, CDI is associated with significant economic burden (approximately $5 billion for U.S. acute care facilities alone5) due to prolongation of hospitalization.
Most often, C. difficile is acquired in healthcare settings: it is the single most common pathogen of acute healthcare-associated infections in the US6. However, about one third of cases are acquired outside healthcare settings, indicating need for prevention beyond the hospital7.
About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.
The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.
Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant).
Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at www.valneva.com.
1 A level of antibodies in the blood directed against the two C. difficile Toxins A and B that is at least 4 times higher after vaccination than before vaccination
2 Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
3 Lessa et al, Clostridium difficile infection. N Engl J Med 2015;372:1539-48).
4 Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
5 Dubberke ER, Clinical Infectious Diseases 55, no. suppl 2 (2012): S88-S92.
6 Magill S, Edwards J R, Bamberg W et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. New England Journal of Medicine 2014;370:1198-208
7 Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
SOURCE: Valneva
Post Views: 266
-
Final Phase II results of Valneva’s Clostridium difficile vaccine candidate confirm positive initial Phase II data that were released at the end of 2015
-
The Phase II study design, which enrolled 500 subjects, had been agreed with regulators with the aim of supporting a progression into Phase III
-
Valneva reaffirms its expectation to enter into a partnering agreement for C. difficile program by the end of year
LYON, France I July 25, 2016 I Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, today announced the successful completion of its Phase II study for its prophylactic vaccine candidate VLA84 targeting primary prevention of C. difficile infection (CDI), which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
Valneva previously announced positive top-line data from the Phase II study at the end of 2015. These initial results, which included data up to Day 56 following initial vaccination, were presented at the American Society of Microbiology’s annual meeting, ASM Microbe 2016, on June 17 in Boston. VLA84 was immunogenic at all doses and formulations tested, in that Immunoglobulin G (IgG) and functional (neutralizing) antibody responses were observed. The study met its primary endpoint in terms of identifying the dose/formulation with the highest seroconversion1 rate against both toxins A and B and confirmed the favorable safety profile observed in Phase I.
Final Phase II results included the follow-up of study participants until Day 210. This long-term data confirmed the optimal vaccine dose and formulation that had been previously identified (high-dose formulation without adjuvant) with an immunogenicity profile at Day 210 in line with expectations. Long-term safety concerns were not seen in any of the different vaccine doses tested.
Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva, commented, “We are pleased with the positive final data generated in this Phase II trial and believe that our C. difficile candidate has the potential to address a growing unmet medical need. Infections caused by C. difficile are responsible for almost 30 thousand deaths every year in the US alone2. There is currently no vaccine on the market that can protect patients and we are determined to find a partner to advance our vaccine candidate further.”
Valneva’s C. difficile Phase II trial was a randomized, placebo-controlled, observer-blind multi-center trial designed to further study and confirm the candidate vaccine’s safety, immunogenicity and proposed doses of immunizations in two different age groups (50 to 64 years of age and 65 years of age and older). The trial was conducted in Germany and the United States under an Investigational New Drug application (IND) and enrolled 500 volunteers who were randomized in several study groups: low-dose vaccine without adjuvant, high-dose vaccine with or without adjuvant (Aluminium hydroxide), or placebo.
Valneva confirmed Phase III readiness through an independent Scientific Advisory Board (SAB) and is ready to support an end-of Phase II meeting (EOP2 meeting) with the regulatory authorities once the final Phase III design has been agreed with a partner. As announced previously, Valneva expects to enter into a partnering agreement for this program by year end 2016.
Currently, no vaccine against C. difficile is approved and antibiotic treatment of the established disease has significant limitations with recurrence in approximately 20% of cases3. The incidence of nosocomial infections is steadily increasing due to the growing number of medical interventions. Valneva estimates that the total market potential for prophylactic C. difficile products may exceed $1 billion annually.
About Clostridium Difficile
C. difficile is a potentially life-threatening bacterium that causes diarrhea and can lead to serious intestinal diseases. It is estimated that 450,000 cases occur annually in the US, and close to 30.000 patients die within 30 days of the diagnosis4.
Beyond the substantial morbidity and mortality, CDI is associated with significant economic burden (approximately $5 billion for U.S. acute care facilities alone5) due to prolongation of hospitalization.
Most often, C. difficile is acquired in healthcare settings: it is the single most common pathogen of acute healthcare-associated infections in the US6. However, about one third of cases are acquired outside healthcare settings, indicating need for prevention beyond the hospital7.
About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.
The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.
Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant).
Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at www.valneva.com.
1 A level of antibodies in the blood directed against the two C. difficile Toxins A and B that is at least 4 times higher after vaccination than before vaccination
2 Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
3 Lessa et al, Clostridium difficile infection. N Engl J Med 2015;372:1539-48).
4 Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
5 Dubberke ER, Clinical Infectious Diseases 55, no. suppl 2 (2012): S88-S92.
6 Magill S, Edwards J R, Bamberg W et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. New England Journal of Medicine 2014;370:1198-208
7 Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
SOURCE: Valneva
Post Views: 266
